Form 4: Organon & Co. Director Ezekowitz Reports Phantom Stock Acquisition

Alan Ezekowitz, a Director at Organon & Co., reported the acquisition of phantom stock units, reflecting a strategic compensation component for non-employee directors.

Summary

• Alan Ezekowitz, a Director at Organon & Co., has filed a Form 4 statement detailing changes in his beneficial ownership.
• The filing reports the acquisition of 17,857.143 phantom stock units on June 12, 2026.
• These phantom stock units are economically equivalent to Organon common stock on a 1-for-1 basis.
• The phantom stock units were granted under the Organon Non-Employee Director Savings Plan.
• These units are payable in cash upon settlement after the reporting person's termination of service as a director.
• The reported holdings also include phantom stock acquired through dividend reinvestment on September 11, 2025, December 11, 2025, March 12, 2026, and June 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation transaction for a director and does not inherently signal positive or negative performance changes for the company.

Positives

• Director Ezekowitz's acquisition of phantom stock units indicates continued engagement and alignment with the company's long-term performance.
• The phantom stock plan provides a mechanism for directors to benefit from the company's growth, aligning their interests with shareholders.
• Dividend reinvestment in phantom stock suggests a positive outlook on future dividend payments and stock value appreciation.

Negatives

• The filing solely reports on phantom stock units, which are not direct ownership of common stock and are payable in cash upon termination, limiting immediate equity participation.
• The value of these phantom stock units is subject to market fluctuations and the company's future performance.

Risks

• The value of the phantom stock units is tied to the future performance of Organon & Co. common stock, which is subject to market volatility and business risks.
• The cash settlement of phantom stock units upon termination of service means directors do not hold actual equity in the company post-service, which could be a risk for long-term shareholder alignment.
• The filing does not provide specific details on the strike price or exercise conditions for the phantom stock, only its economic equivalence to common stock.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a transaction that has already occurred.

Management Comments

• "Each phantom stock unit is an economic equivalent of one share of Organon & Co. ('Organon') common stock, or 1-for-1."
• "Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the 'Plan') and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan."
• "Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026."

Industry Context

StockSavvy.ai notes that the use of phantom stock units is a common practice in corporate compensation, particularly for non-employee directors, to align their interests with shareholders without diluting existing equity. This filing reflects standard executive compensation disclosure practices within the pharmaceutical and healthcare sectors.

Stakeholder Impact

• Shareholders: The transaction reflects standard director compensation, aligning director interests with company performance through phantom stock, which is economically tied to share value.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The filing is a disclosure requirement for management and directors, ensuring transparency in ownership changes.

Next Steps

• The phantom stock units will be settled in cash upon Alan Ezekowitz's termination of service as a director.
• Further dividend reinvestments may occur if applicable under the plan and company policy.

Key Dates

Keywords

Form 4, SEC Filing, Organon & Co., Alan Ezekowitz, Director, Phantom Stock, Beneficial Ownership, Securities Exchange Act, Non-Employee Director Savings Plan, Dividend Reinvestment